Expanding access to Medication Assisted Treatment: The U.S. government’s response to the current heroin epidemic

References

• Appel, P. W., Joseph, H., Kott, A., Nottingham, W., Tasiny, E., & Habel, E. (2001). Selected in-treatment outcomes of long-term methadone maintenance treatment patients in New York State. Mount Sinai Journal of Medicine, 68(1), 55–61.
   PubMed Web of Science ®Google Scholar
• Barceloux, D. G. (2012). Medical Toxicology of Drug Abuse. New York, NY: John Wiley & Sons.
   Google Scholar
• Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Disorders, 31(3), 207–225. doi:10.1080/10550887.2012.694598
   PubMed Web of Science ®Google Scholar
• Beach, S. R., Kostis, W. J., Celano, C. M., Januzzi, J. H. L., Ruskin, J. N., Noseworthy, P. A., & Huffman, J. C. (2014). Meta-analysis of selective serotonin reuptake inhibitor associated QTc prolongation. Journal of Clinical Psychiatry, 75(7), e441–449. doi:10.4088/JCP.13r08672
   Google Scholar
• Botticelli, M. P. (2015, April 1). The federal response to the opioid dependence crisis. American Association for the Treatment of Opioid Dependence Annual Conference. Presented at Addressing a Public Health Crisis: Opioid Dependence, Atlanta, Georgia.
   Google Scholar
• Brady, K. T., McCauley, J. L., & Back, S. E. (2016). Prescription opioid misuse, abuse, and treatment in the United States: An update. American Journal of Psychiatry, 173(1), 18–26. doi:10.1176/appi.ajp.2015.15020262
   PubMed Web of Science ®Google Scholar
• Bride, B. E., Abraham, A. J., Kintzle, S., & Roman, P. M. (2013). Social worker’s knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Social Work in Health Care, 52(1), 43–58. doi:10.1080/00981389.2012.725457
   PubMed Web of Science ®Google Scholar
• Brugal, M. T., Domingo-Salvany, A., Puig, R., Barrio, G., De Olalla, P., & La Fuente, L. (2005). Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction, 100, 981–989. doi:10.1111/add.2005.100.issue-7
   PubMed Web of Science ®Google Scholar
• Bruijnzeel, A. W. (2009). Kappa-opioid receptor signaling and brain reward function. Brain Research Reviews, 62(1), 127–146. doi:10.1016/j.brainresrev.2009.09.008
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. (2015, July). Today’s Heroin Epidemic: More people at risk, multiple drugs abused. Vital Signs. Author. Retrieved August 7, 2015, from http://www.cdc.gov/vitalsigns/pdf/2015-07-vitalsigns.pdf
   Google Scholar
• Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71(7), 821–826. doi:10.1001/jamapsychiatry.2014.366
   PubMed Web of Science ®Google Scholar
• Clark, R. E., & Baxter, J. D. (2013). Responses to state Medicaid programs to buprenorphine diversion: Doing more harm than good. JAMA Internal Medicine, 173(17), 1571–1572. doi:10.1001/jamainternmed.2013.9059
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. (2014 July). Buprenorphine used with treatment resistant depression in older adults. Washington University School of Medicine. Retrieved May 19, 2015, from https://clinicaltrials.gov/ct2/show/NCT02181231
   Google Scholar
• Compton, W. M., & Volkow, N. D. (2006). Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence, 81, 103–107. doi:10.1016/j.drugalcdep.2005.05.009
   PubMed Web of Science ®Google Scholar
• Cone, E. J. (2012). Oral fluid results compared to self-report of recent cocaine and heroin use by methadone maintenance patients. Forensic Science International, 125, 88–91. doi:10.1016/j.forsciint.2011.01.046
   Web of Science ®Google Scholar
• Cowan, A., Friderichs, E., Straβburger, W., & Raffa, R. B. (2005). Basic pharmacology of buprenorphine. In K. Budd, & R. Raffa (Eds.), Buprenorphine—The unique opioid analgesic: pharmacology and clinical application (pp. 3–22). New York, NY: Georg Theime Verlag.
   Google Scholar
• Dahan, A. (2005). New insights into buprenorphine’s respiratory effects. Basic pharmacology of buprenorphine. In K. Budd, & R. Raffa (Eds.), Buprenorphine—The unique opioid analgesic: pharmacology and clinical application (pp. 23–32). New York, NY: Georg Theime Verlag.
   Google Scholar
• Dhalla, I. A., Mamdani, M. M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009). Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Canadian Medical Association Journal, 181(12), 891–896. doi:10.1503/cmaj.090784
   Web of Science ®Google Scholar
• Dole, V. P. (1988). Implications of methadone maintenance for theories of narcotic addiction. Journal of the American Medical Association, 260(20), 3025–3029. doi:10.1001/jama.1988.03410200081030
   PubMed Web of Science ®Google Scholar
• Dole, V. P., Nyswander, M. E., & Kreek, M. J. (1966). Narcotic blockade. Archives of Internal Medicine, 118(4), 304–309. doi:10.1001/archinte.1966.00290160004002
   PubMed Web of Science ®Google Scholar
• Drug Addiction Treatment Act. Public Law 106-310-106, 106 U.S.C.§ 3501 114 STAT. 1223-1227 and § 3502. (2000).
   Google Scholar
• Duffy, P., & Baldwin, H. (2012). The nature of methadone diversion in England: A Merseyside case study. Harm Reduction Journal, 9(3). Retrieved from http://www.harmreductionjournal.com/content/9/1/3
   PubMed Web of Science ®Google Scholar
• Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews, (3), No.: CD002208. doi:10.1002/14651858/CD002208
   PubMedGoogle Scholar
• Fava, M., Memisoglu, A., Thase, M. E., Bodkin, A., Trivedi, M. H., De Somer, M., … Ehrich, E. (2016). Opioid modulation with Buprenorphine/Samidorphan as adjunctive treatment for inadequate response to antidepressants: A randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 173, 499–508. AJP in Advance. doi:10.1176/appi.ajp.2015.15070921
   PubMed Web of Science ®Google Scholar
• Fitzgerald, J., & McCarty, D. (2009). Understanding attitudes toward use of medications in substance abuse treatment: A multilevel approach. Psychological Services, 6, 74–84. doi:10.1037/a0013420
   PubMed Web of Science ®Google Scholar
• Fletcher, A. M. (2012). Inside rehab: The surprising truth about addiction treatment. New York, NY: Penguin Group.
   Google Scholar
• Fortuna, R. J., Robbins, B. W., Caiola, E., Joynt, M., & Halterman, J. S. (2010). Prescribing of controlled medications to adolescents and young adults in the United States. Pediatrics, 126(6), 1108–1116. doi:10.1542/peds.2010-0791
   PubMed Web of Science ®Google Scholar
• Franklin, G. M., Mai, J., Wickizer, T., Turner, J. A., Fulton-Kehoe, D., & Grant, L. (2005). Opioid dosing trends and mortality in Washington State workers’ compensation, 1996-2002. American Journal of Industrial Medicine, 48(2), 91–99. doi:10.1002/(ISSN)1097-0274
   PubMed Web of Science ®Google Scholar
• Gossop, M., & Strang, J. (1991). A comparison of the withdrawal responses of heroin and methadone addicts during detoxification. British Journal of Psychiatry, 158, 697–699. doi:10.1192/bjp.158.5.697
   PubMed Web of Science ®Google Scholar
• Gowing, L., Farrell, M., Bornemann, R., & Ali, R. (2008). Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systemic Reviews, 8, No.: CD004145. doi:10.1002/14651858.CD004145.pub4
   Google Scholar
• Grim, R., & Cherkis, J. (2015, February 5). Federal government set to crack down on drug courts that fail addicts. Huffington Post. Retrieved May 2, 2015, from http://www.huffingtonpost.com/2015/drug-courts-suboxone_n_6625864.html
   Google Scholar
• Haddad, P. M., & Anderson, I. M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62(11), 1649–1671. doi:10.2165/00003495-200262110-00006
   PubMed Web of Science ®Google Scholar
• Hartel, D. M., Schoenbaum, E. E., Selwyn, P. A., Kline, J., Davenny, K., Klein, R. S., & Friedland, G. H. (1995). Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. American Journal of Public Health, 85, 83–88. doi:10.2105/AJPH.85.1.83
   PubMed Web of Science ®Google Scholar
• Hser, Y.-I., Anglin, M. D., & Powers, K. (1993). A 24-year follow-up of California narcotic addicts. Archives of General Psychiatry, 50(7), 577–584. doi:10.1001/archpsyc.1993.01820190079008
   PubMed Web of Science ®Google Scholar
• Hser, Y.-I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotic addicts. Archives of General Psychiatry, 58(5), 503–508. doi:10.1001/archpsyc.58.5.503
   PubMed Web of Science ®Google Scholar
• Johanson, C. E., Arfken, C. L., Di Menza, S., & Schuster, C. R. (2012). Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence, 120(1–3), 190–195. doi:10.1016/j.drugalcdep.2011.07.019
   PubMed Web of Science ®Google Scholar
• Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine, 343(18), 1290–1297. doi:10.1056/NEJM200011023431802
   PubMed Web of Science ®Google Scholar
• Joseph, H. (1994). Methadone maintenance treatment and clinical issues. Retrieved May 2, 2015, from http://methadone.org/library/jospeh_1994_methadone_clinical.html
   Google Scholar
• Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine, 67(5–6), 347–364.
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627. doi:10.1001/archpsyc.62.6.617
   PubMed Web of Science ®Google Scholar
• King, R. (1972). The drug hangup: American’s fifty year folly. Springfield, IL: Charles C. Thomas.
   Google Scholar
• Kintz, P. (2001). Deaths involving buprenorphine: A compendium of French cases. Forensic Science International, 121, 65–69. doi:10.1016/S0379-0738(01)00454-6
   PubMed Web of Science ®Google Scholar
• Knopf, A. (2014, June 23). Congress and administration look at ways to expand buprenorphine treatment. Alcoholism and Drug Abuse Weekly. Retrieved May 2, 2015, from http://www.aslcoholismdrugabuseweekley.com/m-article-detail.congress-and-administration-look-at-ways-to-expand-buprenorphine-treatment
   Google Scholar
• Knopf, A. (2015, February 18). SAMHSA bans drug court grantees from ordering participants off MAT. Alcoholism Drug Abuse Weekly. Retrieved May 2, 2015, from http://alcoholismdrugabuseweekly.com/Article-Detail/samsha-bans-drug-court-grantees-from-ordering-participants-off-Mat
   Google Scholar
• Lagu, T., Anderson, B. J., & Stein, M. (2006). Overdoses among friends: Drug users are willing to administer naloxone to others. Journal of Substance Abuse Treatment, 30, 129–133. doi:10.1016/j.jsat.2005.05.010
   PubMed Web of Science ®Google Scholar
• Langendam, M. W., Van Brussel, G. H. A., Coutinho, R. A., & Van Ameijden, E. J. C. (2001). The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health, 91(5), 774–780. doi:10.2105/AJPH.91.5.774
   PubMed Web of Science ®Google Scholar
• Leal, M. A., & January, C. T. (2013). Cardiovascular effects of methadone. In R. A. Cruciani, & H. Knotkova (Eds.), Handbook of methadone prescribing and buprenorphine therapy, (Chapter 5). New York, NY: Springer.
   Google Scholar
• Leece, P., Cavacuiti, C., Macdonald, E. M., Gomes, T., Kahan, M., Srivastava, A., … Juurlink, D. N. (2015). Predictors of opioid-related death during methadone therapy. Journal of Substance Abuse Treatment, 57, 30–35. doi:10.1016/j.jsat.2015.04.008
   PubMed Web of Science ®Google Scholar
• Lind, B., Chen, S., Weatherburn, D., & Mattick, R. (2005). The effectiveness of methadone maintenance treatment in controlling crime: An Austrailian aggregate-level analysis. British Journal of Criminology, 45, 201–211. doi:10.1093/bjc/azh085
   Web of Science ®Google Scholar
• Lṻscher, C. (2012). Drugs of abuse. In B. G. Katzung, S. B. Masters, & A. J. Trevor (Eds.), Basic and clinical pharmacology (12 ed., pp. 565–580). New York, NY: McGraw Hill.
   Google Scholar
• Madden, M. E., & Shapiro, S. L. (2011). The methadone epidemic: Methadone-related deaths on the rise in Vermont. American Journal of Forensic Medical Pathology, 32(2), 131–135. doi:10.1097/PAF.0b013e3181e8af3d
   PubMed Web of Science ®Google Scholar
• Magura, S. (2009). What more do we need to know about medication assisted treatment for prescription opioid abusers. Addiction, 104, 784–785. doi:10.1111/j.1360-0443.2009.02581.x
   PubMed Web of Science ®Google Scholar
• Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal of Medicine, 68(1), 62–74.
   PubMed Web of Science ®Google Scholar
• Malta, M., Strathdee, S. A., Magnanini, M. M., & Bastos, F. I. (2008). Adherence to antiretroviral therapyfor human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction, 103, 1242–1257. doi:10.1111/j.1360-0443.2008.02269.x
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Systems Review, (3), CD002209. doi:20.1002/14651858.CD002209.pub2
   Google Scholar
• Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Burprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database System Reviews, 16(2), CD002207.
   Google Scholar
• Mazel-Robison, M. S., & Nestler, E. J. (2012). Opiate-induced molecular and cellular plasticity of Ventral Tegmental Area and Locus Coeruleus catecholamine neurons. Perspectives in Medicine, 2, a012070.
   Google Scholar
• McCance-Katz, E. F., Sullivan, L., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. American Journal of Addictions, 19(1), 4–16. doi:10.1111/j.1521-0391.2009.00005.x
   PubMed Web of Science ®Google Scholar
• McKeganey, N., Russell, C., & Cockayne, L. (2013). Medically assisted recovery from opiate dependence within the context of the UK drug strategy: Methadone and Suboxone (buprenorphine-naloxone) patients compared. Journal of Substance Abuse Treatment, 44(1), 97–102. doi:10.1016/j.jsat.2012.04.003
   PubMed Web of Science ®Google Scholar
• Meier, B. (May 10, 2007). In guilty plea, OxyContin maker to pay $600 million. New York Times, Retrieved August 10, 2015, from http://www.nytimes.com/2007/05/10/business/11drug-web.html?_r=0
   Google Scholar
• Metzger, D. S., Navaline, H., & Woody, G. F. (1998). Drug abuse treatment as AIDS prevention. Public Health Reports, 113(1), 97–106.
   PubMedGoogle Scholar
• Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayter, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systemic Reviews, 4, Art. No: CD001333. doi:10.1002/14651858.CD001333.pub4
   PubMed Web of Science ®Google Scholar
• Narcotic Treatment Act, P.L. 93-281, 93-2nd session U.S.C. 88 Stat. 124 (1974).
   Google Scholar
• Nestler, E. J. (2004). Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends in Pharmacological Science, 25(4), 210–218. doi:10.1016/j.tips.2004.02.005
   PubMed Web of Science ®Google Scholar
• Nurco, D. N., Bonito, A. J., Lerner, M., & Balter, M. B. (1975). Studying addicts over time: Methodology and preliminary findings. American Journal of Drug & Alcohol Abuse, 2(2), 183–196. doi:10.3109/00952997509002733
   PubMed Web of Science ®Google Scholar
• O’Connor, P. G., & Fiellin, D. A. (2000). Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine, 133(1), 40–54. doi:10.7326/0003-4819-133-1-200007040-00008
   PubMed Web of Science ®Google Scholar
• Olsen, Y., Daumit, G. L., & Ford, D. E. (2006). Opioid prescriptions by U. S. primary care physicians from 1992 to 2001. Journal of Pain, 7(4), 225–235. doi:10.1016/j.jpain.2005.11.006
   PubMed Web of Science ®Google Scholar
• Phillips, K. A., & Preston, K. L. (2013). Buprenorphine in maintenance therapy. In R. A. Cruciani, & H. Knotkova (Eds.), Handbook of methadone prescribing and buprenorphine therapy, (Chapter 11). New York, NY: Springer.
   Google Scholar
• Potter, J. S., Dreifuss, J. A., Marino, E. N., Provost, S. E., Dodd, D. R., Rice, L. S., … Weiss, R. D. (2015). The multi-site Prescription Opioid Treatment Study: 18-month outcomes. Journal of Substance Abuse Treatment, 48(1), 62–69. doi:10.1016/j.jsat.2014.07.009
   PubMed Web of Science ®Google Scholar
• Preston, K. L. (2005). Buprenorphine for opioid dependence. In K. Budd, & R. Raffa (Eds.), Buprenorphine—The unique opioid analgesic: pharmacology and clinical application (pp. 116–129). New York, NY: Georg Theime Verlag.
   Google Scholar
• Quinones, S. (2014). Dreamland: The true tale of America’s opiate epidemic. New York, NY: Bloomsbury Press.
   Google Scholar
• Redmond, D. E., Kosten, T. R., & Reiser, M. F. (1983). Spontaneous ejaculation associated with anxiety: Psychophysioligical considerations. American Journal of Psychiary, 140(9), 1163–1166. doi:10.1176/ajp.140.9.1163
   PubMed Web of Science ®Google Scholar
• Rieckmann, T. R., Kovas, A. E., McFarland, B. H., & Abraham, A. J. (2011). Counselor attitudes toward the use of buprenorphine in substance abuse treatment: A multi-level modeling approach. Journal of Substance Abuse Treatment, 41(4), 374–385. doi:10.1016/j.jsat.2011.05.005
   PubMed Web of Science ®Google Scholar
• Robins, L. N. (1993). The sixth Thomas James Okey memorial lecture: Vietnam veteran’s rapid recovery form heroin addiction: A fluke or normal expectation? Addiction, 88, 1041–1054. doi:10.1111/j.1360-0443.1993.tb02123.x
   PubMed Web of Science ®Google Scholar
• Roman, P. M., Johnson, J. A., Ducharme, L., & Knudsen, H. K. (2006). Clinical trials network: Counselor-level data on evidence-based treatment practices. Athens, GA: University of Georgia Institute for Behavioral Research.
   Google Scholar
• Sacerdote, P., Franchi, S., Gerra, G., Leccese, V., Panerai, A. E., & Somaini, L. (2008). Buprenorphine and methadone maintenance treatment for heroin addicts preserves immune function. Brain, Behavior, & Immunity, 22(4), 606–613. doi:10.1016/j.bbi.2007.12.013
   PubMed Web of Science ®Google Scholar
• SAMHSA. (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction Tip 40. Rockville, MD: Author.
   Google Scholar
• SAMHSA. (2012). Medication-assisted treatment for opioid addiction in opioid treatment programs: A treatment improvement protocol TIP 43. Rockville, MD: Author.
   Google Scholar
• SAMHSA. (2015a). Grants to expand substance abuse treatment capacity in adult and family drug courts. Retrieved May 2, 2015, from http://www.samhsa.gov/grants-anouncements/ti-15-002
   Google Scholar
• SAMHSA. (2015b, March). Federal Guidelines for Opioid Treatment Programs (HHS Publication No. (SMA) PEP15-fEDGUIDEOTP). Rockville, MD: Author.
   Google Scholar
• Schumacher, M. A., Basbaum, A. I., & Way, W. L. (2013). Opioid analgesics & antagonists. In B. G. Katzung, S. B. Masters, & A. J. Trevor (Eds.), Basic and clinical pharmacology (12 ed., pp. 543–564). New York, NY: McGraw Hill.
   Google Scholar
• Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., … Jaffe, J. (2013). Opioid agonist treatments and heroin overdoes deaths in Baltimore, Maryland, 1995-2009. American Journal of Public Health, 103(5), 917–922. doi:10.2105/AJPH.2012.301049
   PubMed Web of Science ®Google Scholar
• Seewald, R. M. (2013). Use of methadone in opioid maintenance in opioid maintenance treatment. In R. A. Cruciani, & H. Knotkova (Eds.), Handbook of methadone prescribing and buprenorphine therapy, (Chapter 2). New York, NY: Springer.
   Google Scholar
• Shipton, E. A. (2005). Safety and tolerability of buprenorphine. In K. Budd, & R. Raffa (Eds.), Buprenorphine—The unique opioid analgesic: Pharmacology and clinical application (pp. 102–115). New York, NY: Georg Theime Verlag.
   Google Scholar
• Smyth, B., Hoffman, V., Fan, J., & Hser, Y.-I. (2007). Years of potential life lost among heroin addicts 33 years after treatment. Preventive Medicine, 44, 369–374. doi:10.1016/j.ypmed.2006.10.003
   PubMed Web of Science ®Google Scholar
• Sontag, D. (2013, November 16). Addiction treatment with a dark side. New York Times. Retrieved August 15, 2015, from http: nytimes.com/2013/11/17/in-demand-in-clinics-and-on-the-street-bupe-can-be-savior-or-menace.html?_r=0
   Google Scholar
• Spire, B., Lucas, G. M., & Carrieri, M. P. (2007). Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). International Journal of Drug Policy, 18, 262–270. doi:10.1016/j.drugpo.2006.12.014
   PubMed Web of Science ®Google Scholar
• Strang, J., Groshkova, T., & Metrebian, N. (2012). New heroin-assisted treatment. EMCDDA Insights. European Monitoring Centre for Drugs and Drug Addiction. ISSN 1606-1683. Retrieved May 2, 2015, from www.emedda.europa.eu/attachments.cfm/att_154996_EN-Heroin%20Insight.pdf
   Google Scholar
• Streiker, L. H., Comstock, K., Arechiga, S., Mena, J., Hutchins-Jackson, M., & Kelly, K.; Members of the Maintenance and Recovery Relapse Prevention Group. (2013). Medication Assisted treatment (MAT): A dialogue with a multidisciplinary treatment team and their patients. Journal of Social Work Practice in the Addictions, 13, 314–325. doi:10.1080/1533256X.2013.814488
   Google Scholar
• Tetrault, J. M., & O’Connor, P. G. (2011). Management of opioid intoxication and withdrawal. In C. A. Cavacuiti (Ed.), Principles of addiction medicine: The essentials (Chapter 44). New York, NY: Lippincott Williams & Wilkins.
   Google Scholar
• Traynor, J. (2012). μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence, 121(3), 173–180. doi:10.1016/j.drugalcdep.2011.10.027
   PubMed Web of Science ®Google Scholar
• Valliant, G. E. (1973). A 20-year follow-up of New York narcotic addicts. Archives of General Psychiatry, 29(2), 237–241. doi:10.1001/archpsyc.1973.04200020065009
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies—Tackling the opioid-overdose epidemic. New England Journal of Medicine, 370, 2063–2066. doi:10.1056/NEJMp1402780
   PubMed Web of Science ®Google Scholar
• Walsh, S. L., & Middleton, L. S. (2013). Buprenorphine pharmacodynamics and pharmacokinetics. In R. A. Cruciani, & H. Knotkova (Eds.), Handbook of methadone prescribing and buprenorphine therapy (Chapter 12). New York, NY: Springer.
   Google Scholar
• Webster, L. R. (2013). Methadone side effects: Constipation, respiratory depression, sedation, sleep-disordered breathing, and the endocrine system. In R. A. Cruciani, & H. Knotkova (Eds.), Handbook of methadone prescribing and buprenorphine therapy (Chapter 4). New York, NY: Springer.
   Google Scholar
• Weiss, R. D., Potter, J. S., Griffin, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., … Carroll, K. M. (2015). Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug and Alcohol Dependence, 150, 112–119. doi:10.1016/j.drugalcdep.2015.02.030
   PubMed Web of Science ®Google Scholar
• Zedler, B., Xie, L., Wang, L., Joyce, A., Vick, C., Brigham, J., … Murrelle, L. (2015). Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans’ Health Administration patients. Pain Medicine, 16(8), 1566–1579. doi:10.1111/pme.12777
   PubMed Web of Science ®Google Scholar
• Zedler, B., Xie, L., Wang, L., Joyce, A., Vick, C., Kariburyo, F., … Murrelle, L. (2014). Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Medicine, 15, 1911–1929. doi:10.1111/pme.12480
   PubMed Web of Science ®Google Scholar